3 recruiting, 2 completed, 1 active not recruiting, 1 not yet recruiting. 9 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 3, Completed 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 4 | Recruiting 2, Not yet recruiting 1, Withdrawn 1 |
Follow SLE: new trials by email Literature Review of SLE trials Research Report on SLE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus CRC01 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Not yet recruiting | Curocell Inc. | 39 | 2026-02-01 | 2026-01-23 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus VENT-03, Placebo - Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus | Phase 2 | Recruiting | Ventus Therapeutics U.S., Inc. | 24 | 2025-12-03 | 2026-10-05 |
| CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus CART19 - SLE, Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 24 | 2025-05-06 | 2026-09-24 |
| Phase 1b/2a in SLE With Budoputug budoprutug - Systemic Lupus Erythematosus, SLE | Phase 1 / Phase 2 | Withdrawn | Tenet Medicines | 2025-01-01 | 2024-10-16 | |
| A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. APG-2575, Placebo - SLE | Phase 1 / Phase 2 | Recruiting | Ascentage Pharma Group Inc. | 40 | 2024-08-09 | 2025-12-16 |
| Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus Envudeucitinib, Placebo - SLE | Phase 2 | Active not recruiting | Alumis Inc | 408 | 2023-06-26 | 2026-07-21 |
| JBT-101 in Systemic Lupus Erythematosus (SLE) JBT-101, Placebo - Systemic Lupus Erythematosus, SLE | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 109 | 2017-12-21 | 2026-05-06 |
| Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) Mycophenolate Mofetil, Hydroxychloroquine or Chloroquine, Prednisone - Systemic Lupus Erythematosus, SLE | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 102 | 2013-11-20 | 2020-08-17 |
| Vitamin D3 in Systemic Lupus Erythematosus Vitamin D3, Vitamin D3 placebo - Systemic Lupus Erythematosus, SLE | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 57 | 2008-11-01 | 2017-04-26 |
Lupus Erythematosus, Systemic (8) · Lupus Nephritis (2) · Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Immune System Diseases (1) · Lupus Erythematosus, Cutaneous (1) · Musculoskeletal Diseases (1) · Vitamin D Deficiency (1)
Skin and Connective Tissue Diseases (8) · Autoimmune Diseases (7) · Connective Tissue Diseases (7) · Immune System Diseases (7) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Glomerulonephritis (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephritis (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Avitaminosis (1) · Deficiency Diseases (1) · Malnutrition (1)
Adrenal Cortex Hormones (1) · CTL019 chimeric antigen receptor (1) · Chloroquine (1) · Cholecalciferol (1) · Hydroxychloroquine (1) · Lisaftoclax (1) · Mycophenolic Acid (1) · Prednisone (1) · anabasum (1) · chloroquine diphosphate (1) · lenabasum (1)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · Alumis Inc (1) · Ascentage Pharma Group Inc. (1) · Children's Hospital of Philadelphia (1) · Curocell Inc. (1) · Tenet Medicines (1) · Ventus Therapeutics U.S., Inc. (1)
United States (6) · Bulgaria (2) · Georgia (2) · Hungary (2) · Poland (2) · Spain (2) · Argentina (1) · Chile (1) · China (1) · Colombia (1) · Croatia (1) · Denmark (1) · France (1) · Germany (1) · India (1)
Caitlin Elgarten, MD (1) · Cynthia Aranow, MD (1) · Diane Kamen, MD (1) · Eliza Chakravarty, MD (1) · Judith A. James, MD, PhD (1) · Meggan Mackay, M.D., M.S. (1) · Robert B. Zurier, M.D. (1) · Sheng Chen, Ph.D (1)
PMID 25777546, PMID 30454753, PMID 38301682
UM1AI110494 (1)